Journal of Isotopes ›› 2018, Vol. 31 ›› Issue (5): 326-334.DOI: 10.7538/tws.2017.youxian.029

Previous Articles    

The Progress of Nuclear Nanomedicines

ZHANG Huaming;LUO Shunzhong;WEI Hongyuan   

  1. Institute of Nuclear Physics and Chemistry, China Academy of engineering Physics, Mian yang 621999, China
  • Online:2018-10-20 Published:2020-08-14

纳米核药的研究进展

张华明;罗顺忠;魏洪源   

  1. 中国工程物理研究院 核物理与化学研究所,四川  绵阳621999

Abstract:

This manuscript briefly summarized the progress in the last decade and predicted the development in the future of nano-radiopharmaceuticals. The major carrier materials for nanoparticle delivery are biomaterials such as liposomes, or biocompatible materials such as phosphates, hydroxyapatite. Currently, various radionuclides, such as 131I, 111In, 125I, 166Ho, 177Lu, 90Y, 225Ac are extensively used clinically or in research for diagnostic or therapeutic purpose. The preparation methodology of nano-radiopharmaceuticals includes post-irradiation activation, encapsulation, adsorption and etc. Many pre-clinical trials showed that nano-radiopharmaceuticals had displayed good specificity on cancer diagnosis and treatment, thus had became an important research direction in the diagnosis and treatment of cancer and personalized medical care.

Key words: radioactive nuclide, label, nano-technology, nanocarriers materials, nanomedicines

摘要:

本文对近十年纳米核药的研究进展进行综述,展望其发展方向。纳米载体材料以生物材料如脂质体或生物友好材料如磷酸盐、羟基磷灰石等为主。根据诊断和治疗目的选择核素,如131I、111In、125I、166Ho、177Lu、90Y、225Ac等。制备方法包括纳米粒子后辐照活化法、包覆法和吸附法等。大量预临床试验结果表明,纳米核药对肿瘤诊治具有较好的特异性,是肿瘤诊治和个性化医疗研究的重要方向。

关键词: 放射性核素, 标记, 纳米技术, 纳米载体材料, 纳米药物